Role of Matrix Metalloproteinases in Chronic Wound Healing: Diagnostic and Therapeutic Implications
Yanhan Ren,Guosheng Gu,Min Yao,Vickie R. Driver
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20131179
2014-01-01
Abstract:Matrix metalloproteinases (MMPs) are members of the family of zinc-dependent endopeptidases. MMPs are active during normal wound healing, but also in serious illnesses, such as cancers.1 Metalloproteinases participate in the inflammatory stage of wound healing by inducing inflammatory factors and assisting in cellular migration.2 However, when MMPs build up during inflammation,3 the wounds can become chronic and fail to reach the remodeling stage.4 Cell apoptosis, cancer, and other life-threatening illnesses can evolve as the condition worsens, causing the wound to remain permanently open.5 Fortunately, the technology of medical biomarkers has shed light on this endless cycle.6 By determining the baseline for metalloproteinase concentrations near wound sites, physicians may understand the severity or presence of certain disease states and the stage of wound healing. This information might help in deciding whether to inhibit MMPs. However, the prospects for using MMP inhibitors therapeutically and diagnostically face many challenges.7 Chronic wounds Chronic wounds are major burdens for patients, healthcare professionals, and the U.S. healthcare system.8 According to the National Institutes of Health, over five million Americans suffer from chronic ulcers each year,1 and the cost of caring for the ulcers is tremendous. Overall, as much as 20 billion dollars are spent on healthcare every year.7 It has been estimated that 15%-25% of the 27.4 million diabetics in the U.S. in 2010 developed a foot ulcer, a total of about 4.1-6.8 million ulcers. It is also estimated that 15%-20% of diabetics with foot ulcers will undergo limb amputation. The cost of treating diabetic foot ulcers (DFU) is reportedly about $13 000 per episode (up to $30 000 for very severe ulcers). Many of the ulcers are slow to heal or do not heal with conventional treatment and often lead to lower extremity amputation. The direct cost of these amputations in diabetics in the U.S. ranges from $22 700 for a toe amputation, to $51 300 for an above-knee amputation. Ulcers due to venous insufficiency or venous stasis affect 2.5 million patients per year in the United States at an estimated cost of more than $3 billion per year. The recurrence rate of venous stasis ulcers may be as high as 70%.1 In 2009, total treatment costs for diabetic foot ulcer patients with peripheral arterial disease (PAD) were $32 031 per episode.8 In contrast, costs for those with adequate vascular status were $7 182. If about 50% of diabetic foot ulcer patients have PAD, the cost of treating 1.93 million new and old ulcers in 2010 was $61.8 billion; the 2010 cost of treating foot ulcers in patients without PAD was $13.9 billion.9 Physiological wound healing process Wound healing is a complex, dynamic, interactive process involving soluble mediators, blood cells, extracellular matrix, and parenchyma cells.10 Classic wound healing has three sequential, overlapping processes: (1) hemostasis/inflammation, (2) proliferation, and (3) tissue remodeling.11 Inflammation is the beginning of the wound healing processes. The wound becomes red and swollen. Blood clots form at the site for hemostasis.11 Platelets facilitate the formation of a hemostatic plug and secrete several mediators of wound healing, such as platelet-derived growth factor, which attract and activate macrophages and fibroblasts.12 Meanwhile, several vasoactive mediators and chemotactic factors are generated by coagulation and complement pathways and by parenchymal cells, which recruit inflammatory leukocytes to the site of tissue injury.13 Microphages release inflammatory mediators to attack damaged cells and antigens.14 Fibroblasts produce transforming growth factor (TGF), keratinocyte growth factor, and metalloproteinase. Neutrophils produce vascular endothelial growth factor, and fibroblast growth factors.15 The rough blue cells inside the fibrin clot and dermis are macrophages, where antigens are destroyed and the growth factors TGF, fibroblast growth factor, vascular endothelial growth factor, and platelet-derived growth factor (PDGF) are secreted. Also, blood vessels supply platelets to form platelet plugs within the fibrin clot.16 The proliferative phase is characterized by angiogenesis, collagen deposition, granulation tissue formation, epithelialization, and wound contraction.17 After the inflammatory stage, the wound begins to loosen its old epidermal tissue as it prepares for granulation. Uncountable capillaries form under the stroma. At this stage, the concentrations of growth factors and metalloproteinases begin to rise exponentially. Macrophages, neutrophils, and fibroblasts assist in this process by migrating farther into the wound space.11 MMP-1, 2, 3, and 13, along with urokinase-type plasminogen activator, are released into blood vessels. New vessels and neurons form beneath the clot. Epithelial cells close the wound sites and separate the fibrin clot from the newly formed tissues. Tissue inhibitor metalloproteinase (TIMP) begins to neutralize the MMPs used in wound healing.18 When the levels of collagen production and degradation equalize, the maturation phase of tissue repair begins. This phase includes wound contraction and extracellular-matrix reorganization. Wound contraction involves a complex interaction of cells, extracellular matrix, and cytokines.11 The appearance of the myofibroblasts corresponds to the commencement of connective-tissue compaction and contraction of the wound. The contraction probably requires stimulation by TGF β1 or β2 and PDGF.19 Formation and contraction of new matrix rely on distinct combinations of MMPs and TIMP. Reduced organization and deposition of cutaneous collagen fibrils suggest that collagen-mediated wound contraction and closure may be negatively affected. Similarly, osteopontin plays an important role in collagen re-modeling. Another matricellular protein, vitronectin, may also affect collagen-mediated contraction.17 Chronic wound healing Wounds can be classified as acute or chronic depending on their state of healing.20 Acute wounds follow the wound healing process described above. Disruption of any stage in this complex cascade may lead to chronicity. Acute wounds appear to have a balance between degradation and production of certain molecules, such as growth factors, proteinase, collagen, cytokines, and other biological factors. On the other hand, Chronic wounds have prolonged inflammation, impaired neovascularization, decreased synthesis of collagen, increased levels of proteinase, and defective macrophage function.21 Multiple physiologic and biochemical defects can lead to impairment of wound healing. Impaired wound healing usually occurs in patients with neuropathy, who cannot sense and relieve cutaneous pressure.22 Ischemia also impedes healing by reducing the supply of oxygen and other nutrients to the wound.22 Other abnormalities associated with abnormal wound healing include prolonged inflammation, impaired neovascularization, decreased synthesis of collagen, increased levels of proteinases, and defective macrophage function.23 MMPs: structure, family, function, and classification The MMP family consists of more than 24 structurally related, zinc-dependent endopeptidases that are capable of degrading various components of the extracellular matrix (ECM). MMPs play a pivotal role in the ECM remodeling that accompanies several physiologic processes of wound healing.2 MMPs are secreted from various immune cells, including macrophages and neutrophils, and reconstructive cells, such as fibroblasts. Most members of the MMP family are organized into three basic, distinct, and well-conserved domains based on structural considerations: an amino-terminal propeptide, a catalytic domain, and a hemopexin-like domain at the carboxy-terminal position. MMPs play important roles in the influx of leukocytes, angiogenesis, re-epithelialization, and tissue remodeling.24 MMPs also degrade growth factors and their receptors, as well as angiogenic factors. Control of these various elements by MMPs determines, in part, whether angiogenesis will be stimulated or inhibited. MMPs also contribute to the liberation of growth factors, cleave ECM proteins, and reveal regions that can activate growth factor receptors.2 Thus, MMPs act not only to degrade and remodel selected ECM components at appropriate times, but also to reveal selected bioactive ECM segments through targeted cleavage that ultimately influences cellular behavior. During wound healing, keratinocytes at the wound edge begin producing MMPs as the cells detach from the basement membrane and migrate across the wound bed. Production of MMPs is regulated by cellular interactions with the matrix, as demonstrated by the ability of human keratinocytes grown on native type I collagen, but not on denatured collagen or matrigel, to express high levels of MMPs. These data provide another example of the ECM’s regulation of the patterns and amounts of cellular gene expression. Although controlled production of proteases is critical to normal wound healing, chronically elevated levels of certain MMPs can lead to matrix degradation and impaired wound healing.4 TIMP consists of 184-194 amino acids that are inhibitors of MMPs.25 A family of TIMP consists of four members, TIMP-1, 2, 3, and 4, with each having an N-terminal and a C-terminal subdomain.25 Each domain contains three conserved disulfide bonds, and the N-terminal domain folds as an independent unit with MMP inhibitory activity.26,27 TIMP-1 is able to inhibit the activity of all known MMPs. In chronic wounds, TIMP-1 is absent or significantly lower than in normally healing wounds.28 TIMP-2 mainly acts as an effective inhibitor of pro and active MMP-2. TIMP-3 inhibits the activity of MMP-1, 2, 3, 9, and 13.28 Role of MMPs in the process of wound healing Activities of multiple metalloproteinases, including MMP-1, 2, 3, 7, 9, 10, and 28, are increased during inflammation.29 The MMPs act as blades, cutting the damaged epithelium cells apart to permit cell mitigation, allowing neutrophils and macrophages to enter the wound for rehabilitation. Metalloproteinases accomplish this by directing chemokine activities. After that, a strong chemo-gradient is created by metalloproteinase-1, 3, and 9, which are the dominant metalloproteinase during regulation.30 Studies have proven that most MMPs are made by fibroblasts and certain leukocytes, such as neutrophils and macrophages.2 In addition, chemokine groups CXCL and CCL, stimulated by metalloproteinases, help to recruit inflammatory cells, an action that promotes faster repair of wounds.27 MMPs are found in all human cutaneous wounds during remodeling but disperse immediately after the wound is closed. Meanwhile, keratinocytes migrate through the dermal matrix when the collagen-integrin is lessened by MMP.31 MMPs act like a key regulator in both long-term and short-term wounds. This activity was proven in a recent experiment in which MMPs were present on the edge of wound sites when artificial wounds were made in rabbits. Besides MMP-1, MMP-7 is responsible for repairing multiple ulcers.32 Other types of MMPs, namely MMP-2, 3, and 10, demonstrate less activation during re-epithelialization and are located behind the front of cell migration. These MMPs also are involved in wound healing but not in the epithelial stage since they, especially MMP-10, have certain chemical responses that would cause complications, and so they remain quiescent until the re-epithelial stage.33 Researchers have suggested that over expression of MMP-10 leads to decreased concentrations of lamini-5. This effect could seriously affect ECM cell signals and result in keratinocyte apoptosis, with reversal of the wound healing to the inflammatory stage, resulting in chronic ulcer.34 MMPs and DFU An estimated 23.6 million Americans have diabetes mellitus, a 30% increase in the prevalence of this disease over the preceding 5 years.35 The annual cost of care of DFU, including amputation, is more than 10 billion dollars. The lifetime risk of developing a foot ulcer in diabetics is 15%. In diabetics who have sensory neuropathy, the annual incidence increases to about 6%.36-38 DFUs precede 85% of the lower limb amputations, and one in six patients with DFU eventually requires an amputation.39,40 The pathophysiology of DFUs is complex. It is characterized by the presence of an inflammatory reaction, with the participation of leukocytes, lymphocytes, and macrophages. Deficits in more than 100 physiologic factors may contribute to defective wound healing in diabetic patients.41,42 Schultz et al43 have listed a series of such abnormalities, including microvascular impairment, pericyte degeneration, basement membrane thickening, glycation of fibronectin and collagen, deficits in the bactericidal action of granulocytes, and altered leukocyte infiltration in the late inflammatory phase. Diabetic ulcers are believed to be caused by diabetic neuropathy and chronic trauma, impaired microvascular circulation, and peripheral arterial disease. The exposure of endothelial cells, macrophages, and smooth muscle cells to high concentrations of glucose induces a dysregulation of the MMP-TIMP balance.44,45 It is postulated that glucose upregulates MMP gene expression via its effects on transcriptional factors AP-1, NF-kB, PDGF, and TGF-β.46-51 Insulin resistance stimulates the expression and activity of MMP-9 and -2.52,53 Elevation in serum MMP-9 is associated with progression and development of diabetic neuropathy.54 In a rat model of preclinical type 2 diabetes,55 27 ECM genes and the expression of MMPs and ECM proteins were increased in comparison with amounts in control animals. Diabetes also is associated with the glycation of several ECM proteins, including collagen and fibronectin, an alteration that reduces their ability to adhere to cells. Furthermore, Cullen et al56 tested levels of proteases in an ex vivo wound fluid model, and showed that the addition of this test material to chronic wound fluid obtained from DFU patients resulted in a significant reduction in the activities of neutrophil-derived elastase, plasmin, and MMPs when compared with activities in wet gauze. Plasma concentrations of MMP-2 and 9 are elevated in diabetics, as are the levels of TIMP-1 and 2, indicating potential abnormalities in ECM metabolism.57 Muller et al58 studied 16 patients with neuropathic DFUs, collecting wound fluid regularly during a 12-week period for measurement of MMP-1, 2, 8, 9, and TIMP-1. Wound healing was defined as good, with reduction of at least 82% in initial wound surface at 4 weeks, or poor, with reduction less than 40%. Initial levels of MMP-1 were similar in good and poor healers but rose significantly at Week 2 in good healers. A significant correlation was present between a high ratio of MMP-1/TIMP-1 and ROC analysis showed that an MMP-1/TIMP-1 ratio of 0.39 best predicted wound healing (sensitivity =71%, specificity =87.5%). The authors concluded that a high level of MMP-1 may be essential for wound healing, whereas an excess of MMP-8 and 9 is unfavorable. The MMP-1/TIMP-1 ratio is a predictor of wound healing in foot ulcers.58 Moreover, another DFU study exploring MMP/TIMP ratios found that MMP-9 and the MMP-9/TIMP-1 ratio correlated inversely with the wound healing rate at 28 days.59,60 MMP-9 and the MMP-9-to-TIMP-1 ratio were lower in 23 patients who achieved complete healing at 12 weeks compared with values in 39 who did not. The pro-MMP-9 concentration was predictive of healing within 12 weeks. Addition of cutoffs for TIMP-1 (>480 pg/ml) and TGF-β (>115 pg/ml) further improved its predictive power (area under the curve 0.94). These findings suggest that a milieu with high MMP-9 may be indicative of inflammation and poor wound healing. Measurements of MMP-9, TIMP-1, and TGF-β in wound fluid may help to identify ulcers at risk of poor healing.58-60 Ulrich et al61 investigated the effect of treatment with oxidized regenerated cellulose/collagen matrix on the concentration and activity of gelatinases, elastase, and plasmin in wound exudates of 32 foot ulcers. Wound exudate was collected on Days 0, 5, 14, and every 14 days thereafter for 12 weeks. Exudates of treated patients’ ulcers had significantly decreased amounts of elastase, plasmin, and gelatinase activities. The MMP-2 concentration was significantly reduced on Days 14, 28, 42, and 56 in comparison with Day 0. Furthermore, wound size was significantly reduced at Days 14 and 28 in the treated patients. The results showed a significant and immediate reduction in the levels of all tested proteases, consistent with reduction of wound size, in the wound exudate of DFU patients treated with oxidized regenerated cellulose/collagen matrix. In another study, impairment of wound healing was seen also in chronic periodontitis with type 2 diabetes patients, in whom concentrations of C-reactive protein, MMP-14, and TIMP-2 in inflamed tissue were elevated.62 MMPs and venous stasis ulcers Venous stasis ulcers are another common type of lower extremity chronic ulcers. The ulcers develop as a result of advanced chronic venous insufficiency (either primary venous incompetence or the post-thrombotic syndrome).63-65 The overall incidence of venous ulcers in patients 45 years or above is about 3.5 per thousand per year, and the ulcers affect almost 1 million Americans.66 Delayed healing and frequent recurrence of the ulcers result in pain, disability, decreased quality of life, and loss of working days.63 The cost to healthcare systems of chronic venous ulcers is massive; the direct medical costs alone have been estimated to be up to 3.5 billion annually.67 The pathogenesis of venous ulcers is characterized by chronic inflammation, degradation, and transformation within vein walls.68,69 The resulting decreased vessel wall strength, alteration in ECM contents, and MMP dysregulation play a key role. The exact role of MMPs in venous ulcer pathogenesis remains unclear. Over activity of MMP-2 may inhibit wound healing via excessive degradation of basement membrane leading to loss of epidermal integrity. Diminished angiogenesis induced by exudate collected from chronic venous wounds has been demonstrated.70 The decreased angiogenesis was reversed by addition of an inhibitor of MMP-1 and -9, suggesting that MMP imbalance in chronic venous ulcers has an anti-angiogenic effect.71,72 Interstitial collagen III is important for stretch resistance of the connective tissue of veins. MMPs contribute to weakness of vein walls and varicose vein formation via excessive degradation of collagen III.71 Kowalewski et al73 compared MMP levels in the walls of normal veins, varicose veins, and varicose veins complicated by thrombophlebitis. The authors found that MMP-1, 2, 3, and 9 concentrations in varicose vein biopsy specimens were almost twice as high as those in healthy veins. The walls of varicose veins, particularly those complicated by thrombophlebitis, had extensive alterations in the content and activity of MMPs; these affects may induce ECM remodeling, influence mechanical properties of the vein wall, and predispose to progression of the disease. MMP zymography, a method to directly determine proteolytic activity of MMPs, has revealed that increased activities of MMP-2, MT1-MMP, and MT2-MMP in dermal structures of venous leg ulcers may favor enhanced turnover of the ECM.74 This observation leads to speculation that MMPs could be therapeutically beneficial in the management of late complications of chronic venous ulcers.75,76 The zymographic studies provided direct evidence of elevated expression of MMP at the mRNA and protein levels in venous leg ulcers compared with values in healthy skin. Intense expression of extracellular matrix metalloproteinase inducer (EMMPRIN), MMP-2, MT1-MMP, and MT2-MMP were revealed by immunohistochemistry in dermal structures of venous leg ulcers, whereas expression of EMMPRIN and MMP-2 was increased only in perivascular regions. Venous leg ulcers are characterized by elevated expression of EMMPRIN, MMP-2, MT1-MMP, and MT2-MMP. Membrane-bound MMPs may favor enhanced turnover of the extracellular matrix and support unrestrained MMP activity in venous leg ulcers.75,76 One hundred and ten biopsy specimens from the lower calf and lower thigh in 73 patients were stratified into six groups according to the disease cause.77 The authors found that MMP synthesis was regulated at both the transcriptional and post-transcriptional levels in chronic venous insufficiency, and alterations in MMP-2 activity, in conjunction with TGF-β(1)-mediated events, cause an imbalance in tissue remodeling leading to a pro-ulcer-forming environment.77 Healing of venous ulcers is associated with expression of a wide range of MMPs. Compression therapy results in a reduction of the pro-inflammatory environment characteristic of chronic venous ulcers, and ulcer healing is associated with reversal of elevated expression of certain proteases.78 MMP-8 and 9 were highly expressed in ulcer tissue. MMP-3, 8, and 9 were significantly decreased after 4-week compression treatments. Reduction in the levels of MMP-1, 2, and 3 was associated with significantly higher rates of ulcer healing. Pro-inflammatory cytokines may also interact with MMPs in nonhealing venous wounds. The exudate in chronic venous ulcers contains increased amounts of gelatinases (MMP-2 and -9) and decreased amounts of TIMPs. Nonhealing venous ulcers have increased amounts of TNF-α, IL-1β, and IL-6, which are responsible for upregulating MMPs.79,80 As in other types of chronic wounds, the MMP/TIMP ratio in chronic venous ulcers is closely associated with healing rate. Mwaura et al81 measured the expression of MMP-2 and TIMP-2 in the ulcer exudates and perivascular tissue of healing and nonhealing chronic venous ulcers in 40 patients. The authors found that high levels of MMP-2 and low levels of TIMP-2 in the wound fluid were strongly correlated with the state of healing; nonhealing venous ulcers were associated with greater MMP-2 activity. MMPs and arterial ulcers Arterial leg ulcers, a complication of PAD, are a consequence of inadequate blood supply to the skin. PAD is present in about 20% of adults older than 55 years.82-84 Atherosclerotic disease is the most common cause of PAD, but thromboembolic disease also can cause infarction of skin and lead to ulcer formation. The risk for lower extremity arterial ulceration is increased in smokers, diabetics, elderly patients, and persons who have arterial disease at other sites. The typical clinical manifestation of PAD is intermittent claudication, with leg pain developing upon exercise; pain at rest, leg ulcers, and gangrene develop in later stages.85,86 Cool feet, weak pedal pulses, and slow refilling of toe capillaries on physical examination support the diagnosis of arterial insufficiency. Doppler ultrasound assessment of the distal pulses, Ankle Brachial Index, and Toe Brachial Index can confirm a compromised limb arterial supply. Arterial ulcers usually are round with a sharply demarcated border. They typically occur distally, often over bony prominences. The surrounding skin may be hairless, shiny, and atrophic. Pain at the ulcer sites often is significant and is exacerbated by leg elevation. Arterial leg ulcers may benefit from surgical correction of the underlying vascular problem and restoration of peripheral blood flow. Arterial disease is present in about 25% of patients with leg ulcers. Ulcers of mixed arterial and venous cause are common. MMPs play a role in PAD. MMP-2 and 9 have been implicated in multiple mechanisms of angiogenic response to ischemia. The ischemic muscle is a source of MMPs. MMPs promote angiogenesis by degrading ECM and regulating VEGF. Muhs et al87 studied limb ischemia in a mouse model of unilateral femoral artery ligation. The gastrocnemius muscle was harvested from the ischemic limbs and limbs of control animals at 1, 3, 14, and 30 days after ligation and the tissue was assayed for MMP-2, 9, and MT1-MMP. Gelatin zymograph analysis revealed a 212% increase in active MMP-2, three days after ligation, and active MMP-9 reached its maximum level (800% over baseline) on postoperative Day 3 and remained elevated on Day 14 (737% over baseline). The increase in active MMP-2 and 9 levels paralleled PMN infiltration, which also peaked three days after ligation (1184% over baseline). PMN count, MMP-2, and 9 all returned to baseline levels by postoperative Day 30. Limb ischemia causes an early activation of MMP-2 and 9, which is temporally correlated with PMN infiltration. Limb ischemia may prime PMNs, leading to their sequestration in ischemic tissue. In the model, PMN depletion was associated with reduction in the elevated MMP activity, which is evidence that MMP activity was mediated through PMNs.88 In another study with a limb ischemia model using various MMP-2-lacZ reporter mice, Lee et al89 determined transcriptional activation of the MMP-2 gene. Both MMP-2 activity and mRNA were increased after limb ischemia. Deletion of MMP-2 led to impaired restoration of perfusion and a higher incidence of limb gangrene. Ischemia induces expression and binding of c-Fos, c-Jun, Jun B, Fos B, and Fra2 to the activating protein-1 site present in the MMP-2 promoter, and decreased binding of the transcriptional repressor Jun D. These events likely are the explanation for involvement of MMP regulation in ischemia-induced revascularation. Single nucleotide polymorphisms in genes encoding inflammatory molecules may determine genetic profiles associated with increased risk of peripheral arterial occlusive disease (PAOD) and critical limb ischemia. IL-6, E-Selectin, ICAM-1, MCP-1, MMP-1, and MMP-3 gene polymorphisms were found significantly and independently associated with PAOD.90 These pro-inflammatory polymorphisms determine genetic profiles that are associated with various levels of risk for PAOD and critical limb ischemia, depending on the number of high-risk genotypes concomitantly carried by a given person. In patients with intermittent claudication and critical limb ischemia, it has been reported that circulating levels of MMP-9, TIMP-1, and TIMP-2 were elevated in comparison with levels in healthy controls, a finding which reflected an increase in proteolytic activity that may be related to ECM turnover in PAD. Tayebjee et al91 investigated 36 patients with intermittent claudication and 43 with critical ischemia. Circulating levels of MMP-9 and TIMP-1 were higher in the intermittent claudication patients than in the controls. There were no differences in circulating TIMP-2 levels between patients and controls, but a positive correlation was found between the white cell count and MMP-9 in patients with intermittent claudication. Circulating concentrations of both markers (MMP-9 and TIMP-1) may be indicators of disease severity, being higher in critical ischemia compared with levels in intermittent claudication. Patients with diabetes and PAD have a five-fold increase in the rate of amputation caused by critical limb ischemia compared with nondiabetics. Diabetes alters the expression and function of MMPs, which may accelerate the progression of PAD. Circulating MMP-2 and -9 levels are higher in diabetic patients who have PAD than in nondiabetic patients with PAD. MMP-9 might also be released by circulating neutrophils or monocytes as a consequence of a pro-inflammatory state.91,92 MMPs and pressure ulcers Every year, tens of thousands of patients develop pressure ulcers. A survey among selected sites in the United States in 2009 found an overall prevalence of pressure ulcers of 11.9% and a facility-acquired rate of 5.0% in acute care facilities.93 Along with pain and serious infections, pressure ulcers result in increased healthcare use and cost. A study using Medicare inpatient data found that pressure ulcers accounted for up to 2.4 billion dollars in excess healthcare cost.94 Major physical factors leading to the formation of pressure ulcers are the intensity and duration of pressure, low tissue tolerance, shear forces (iatrogenic, for instance, when patients are moved by staff), friction (secondary to patients movement in bed), moisture (most often due to urinary and fecal incontinence), and nutritional debilitation. Bony prominences that are at highest risk for the development of pressure ulcers are the occiput, scapulae, elbows, greater trochanters, ischial tuberosities, sacrum/coccyx, malleoli, and heels. Two-thirds of all pressure ulcers in immobilized patients occur in the pelvic girdle region.95 Prolonged pressure on tissue leads to occlusion of the microvasculature and consequent tissue hypoxia. These events lead to localized tissue ischemia, resulting in the development of inflammation, increased vascular permeability, and protein accumulation in the local interstitium.96 Increased tissue edema and the worsening of perfusion follow, and this vicious cycle ultimately results in the development of a pressure ulcer. Pressure ulcers have elevated MMP-1, 2, 8, and 9 concentrations and lower concentration of TIMP-1 compared with concentrations in normally healing wounds. Thus, the MMP-9/TIMP-1 ratio is significantly higher in pressure ulcers than in normally healing wounds.97 Ladwig et al98 measured MMP-2, MMP-9, TIMP-1, TIMP-2, and the ratios of MMP/TIMP in fluids and biopsy specimens collected from 56 patients with chronic pressure ulcers treated for 0, 10, and 36 days with conventional therapy or with exogenous cytokines. The average MMP-9/TIMP-1 ratio in fluids from 56 ulcers decreased significantly as the ulcers healed. Furthermore, the average MMP-9/TIMP-1 ratio was significantly lower in fluids collected on Day 0 from wounds that ultimately healed well (≥85% reduction in initial wound volume) compared with wounds that healed poorly (<50% wound volume reduction). These data indicate that the ratio of MMP-9/TIMP-1 levels is a predictor of healing in pressure ulcers, and they provide additional support for the hypothesis that high levels of MMP activity and low levels of MMP inhibitor impair wound healing in chronic pressure ulcers. Biomarkers and diagnostic values of MMPs Biomarker is defined as a substance that can be objectively measured and evaluated as an indicator of normal physiologic processes or pathogenic processes, or of pharmacologic responses to a therapeutic intervention. Assays using patients’ tissues and gene products in the management of some diseases already are available. Examples are alpha fetal protein,99 carcinoembryonic antigen,100 Oncotype DX,101 C-reactive protein,102 and erythrocyte sedimentation rate.103 Biochemical characterization of wound fluids presents an opportunity to noninvasively define the status of wounds and of specific biomarkers. Only a few studies of biomarkers in chronic wounds have been conducted. The development of innovative strategies to promote tissue repair is, therefore, an important task that requires a more thorough analysis of the underlying molecular pathophysiology. Eming et al104 identified 149 differential specific protein profiles that were characteristic of a persistent inflammatory and tissue destructive response. Surgical debridement is routinely performed on chronic wounds because it stimulates healing. Brem et al105 developed bioassays that assessed the pathogenesis of wound tissue before and after wound debridement, and that may guide the use of surgical debridement. Tissues were obtained from three patients at two locations, and the authors found that nonhealing wound edges had a specific, identifiable, and reproducible gene expression profile, which was distinct from the profile of adjacent nonulcerated tissue. Thus, it appears that particular wound areas can be identified by gene expression profiling. Perhaps identification of these molecular markers will help guide surgical debridement to make it more accurate and efficacious. Yager et al106 have discussed the potential biomarkers, proteases, proteinase inhibitors, and pro-inflammatory cytokines, isolated from wound fluids to determine the wound status. MMPs received the most attention on the studies of chronic wounds. Many chronic wounds become stuck in the inflammatory phase of healing despite good basic wound care. An expert panel has concluded that wound care lacks specific diagnostic tests that can be used to direct specific therapies. They agreed that appropriate proteinase activity was important in wound healing. However, measurement of only an individual protease likely would not be representative of the proteolytic environment of the wound. However, a wider-spectrum, practical test might be useful in directing wound care, especially in outpatient settings. The general way to conduct point-of-care (POC) tests using MMPs as biomarkers is to assess the MMP reading where the wound occurs and set up this as a baseline for further measurements. It is during this process that it may become evident that the wound is a chronic wound. If so, physicians would like to determine if protease activity is elevated over a certain period of time. Because confounding factors may interfere with a protease test, timing of the POC test would be critical. For example, the test might be taken after cleansing but before debridement, depending on presence of slough, necrotic tissue, or debris.107 Based on the present findings, a POC test could be conducted four weeks after the initial visit and thereafter at two-week intervals. The two-week period may be adequate to allow the effects of a treatment to elapse before retesting, and for levels of MMP activity to dissipate. With this strategy, physicians may avoid the mistakes caused by blind prescribing. For example, if the POC tests show when a site is stuck in the inflammatory stage during wound healing, then excessive amounts of MMPs are present. This information could prompt clinicians to prescribe the right amounts of inhibitory agents. Such a test could also save on resources and energy of the healthcare facilities and benefit patients economically.107 Galliera et al108 measured MMP-2 and 9 concentrations in subacromial fluid of 23 patients. Peripheral blood levels of MMP-2 were similar to levels in subacromial fluids, whereas the MMP-9 level was higher in the subacromial space than in the peripheral blood. This work suggests that the measurement of bone-specific MMPs (MMP-2 and MMP-9) can be useful when monitored in parallel with measurement of growth factors and other bone-turnover markers in evaluating bone remodeling and tissue healing. Implications of targeting MMP therapeutics in wound care Given the important roles that MMPs play in tumor growth and metastasis, and the dysregulated angiogenesis that drives these conditions, the development of clinically useful antagonists of this enzyme family is worth pursuing. Metalloproteinase inhibitors have been or are currently being tested in clinical trials against a variety of human diseases, many of which are cancer related.109 Novel approaches to inhibition of MMP activity are being tested in chronic wound care. It was shown that docycycline and other tetracyclines inhibited MMP activity.110 In a pilot study, Chin and colleagues examined fluids from diabetic foot ulcers and found that the addition of doxycycline at 50, 500, and 5000 mM significantly reduced protease activity (by 44%, 75%, and 89% respectively). Chronic wounds treated with 1% topical doxycycline healed in 4, 7, 24, and 30 weeks; in contrast, wounds in only one of three patients treated with placebo hydrogel healed during the initial 20-week treatment period. Another mechanism by which doxycycline may facilitate the healing of ulcers is through indirect inhibition of serine proteases. When topically applied to diabetic ulcers, doxycycline lowered the levels of serine proteases. A prospective, controlled trial has been conducted to examine the biological response of subantimicrobial-dose doxycycline combined with access flap surgery on periodontal wound repair in patients with chronic severe periodontitis. Patients treated with this form of doxycycline and surgery had reduced depth of surgically treated sites and increased levels of clinical attachment, suggesting that the doxycycline improved the short-term response to periodontal surgical therapy.111 Another study showed that the excessive MMP activity in chronic wound fluid can be inhibited by the bisphosphonate alendronate, in the form of a sodium salt, which is a functionalized analogue tethered to a poly(2-hydroxy methacrylate) hydrogel.110 This hydrogel appears to be biologically inert, as assessed in a three-dimensional ex vivo human skin model. This approach improved wound healing, as it still allowed MMPs to remain active in the upper cellular layers of the ulcer bed. A new device-orientated wound therapy seems attractive Despite the progress being made, the results of attempts to reduce MMP activity in wound care have not been impressive. An important point when considering the use of MMP inhibitors is that broad-spectrum inhibitors should be avoided, as that MMPs have a broad range of activities and are not only involved in wound healing but also in many other physiological processes. Therefore, it is crucial to determine the role of various MMPs, so that wound-specific inhibitors can be applied.111